, Singapore
514 views
Pfizer

MOH lists abrocitinib on the medical assistance fund

The drug is used to treat atopic dermatitis.

The Ministry of Health (MOH) will list abrocitinib on its Medication Assistance Fund (MAF) on 1 March 2024.

Pfizer's abrocitinib is an oral tablet used to treat moderate-to-severe atopic dermatitis (AD). Eligible patients can now access alternative treatment options from public healthcare institutions.

Abrocitinib has been studied in the JADE clinical program, which involved over 3,800 adults and adolescents with moderate-to-severe AD.

Patients who received abrocitinib reported rapid relief from chronic itch and significant improvements in skin clearance.

“The subsidization of newer therapeutics will now improve accessibility to treatments for AD patients who rely on alternative treatments to manage their symptoms,” Ursula Soh, founder of Eczema Support Group Singapore (ESGS) said.

Follow the link for more news on

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!